What Is Xyngari and How Does It Treat Acne
Xyngari is a once-weekly topical treatment for moderate to severe acne vulgaris developed by Dermata Therapeutics. It uses proprietary Spongilla technology to target the underlying mechanisms of acne with precision, aiming for better results and fewer side effects.
Acne happens when pores get clogged with oil, dead skin, and bacteria, leading to inflammation and breakouts. Xyngari works by delivering active ingredients directly to the skin through natural sponge spicules from Spongilla lacustris, a freshwater sponge. These tiny structures gently exfoliate the skin, reduce inflammation, kill acne-causing bacteria, and regulate oil production. Patients apply it just once a week, making it easier to use than daily creams.
The treatment showed strong results in the Phase 3 STAR-1 clinical trial. In this study, Xyngari met all three main goals: it significantly reduced inflammatory lesions, non-inflammatory lesions, and total lesions compared to placebo. Effects started as early as four weeks and continued to improve through twelve weeks. It was safe and well-tolerated, with few side effects and no serious problems linked to the treatment.
Dermata Therapeutics recently decided to shift Xyngari from a prescription drug to an over-the-counter skin care product. They pulled their FDA application to focus on broader uses of the Spongilla technology in everyday skin care items. An abstract with more trial details is set for presentation at the European Academy of Dermatology and Venereology Congress in 2025.
This approach could make effective acne treatment more accessible for people dealing with stubborn breakouts.
Sources
https://www.stocktitan.net/news/DRMA/
https://www.bioworld.com/content/phase3-data-2025
